← All trials
NCT05317689
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2022
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Apr 8, 2022
- Last posted
- Oct 14, 2022
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- University of California, San FranciscoSponsor investigator
- University of California, San FranciscoOfficial
- Filament Health Corp.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.